Anticipatory Nausea and Vomiting: Evidence‑Based Management

Pharmacologic Treatment

Lorazepam 1 mg orally at bedtime the night before chemotherapy and 1 mg the morning of chemotherapy reduces the incidence of anticipatory nausea and vomiting in adult cancer patients receiving chemotherapy (Mayo Clinic guideline) 1.
Alprazolam 0.25–0.5 mg orally three times daily, starting the night before treatment, is an effective alternative benzodiazepine for anticipatory emesis (National Comprehensive Cancer Network – NCCN) 3.
Lorazepam should be used as an adjunct to standard antiemetic regimens (5‑HT₃ antagonists, NK1 antagonists, dexamethasone); the combination provides comprehensive control of acute, delayed, and anticipatory emesis (American Society of Clinical Oncology – ASCO) 6, 8.

Administer the most active antiemetic regimen appropriate for the chemotherapy regimen from the first treatment cycle; this strategy markedly lowers the risk of developing anticipatory symptoms (ASCO) 4, 5.
Avoid “test” regimens that are less effective, as they increase the likelihood of conditioned anticipatory nausea and vomiting (ASCO) 4, 5.

Systematic desensitization, when added to pharmacologic prophylaxis, significantly reduces anticipatory nausea (relative risk ≈ 0.60) and vomiting (relative risk ≈ 0.54) in patients who have already developed symptoms (NCCN) 3.
Hypnosis combined with systematic desensitization may be beneficial as an adjunctive behavioral therapy (NCCN) 3.
Guided imagery has demonstrated modest efficacy as an adjunct to medication for anticipatory emesis (NCCN) 3.

Benzodiazepines (e.g., lorazepam, alprazolam) are useful adjuncts but should never be used as sole antiemetic agents for chemotherapy‑induced nausea and vomiting (ASCO) 6, 7.
Elderly patients are more sensitive to benzodiazepine effects; a lower starting dose of alprazolam (0.25 mg orally 2–3 times daily) is recommended (NCCN) 3.
When discontinuing benzodiazepine therapy, taper the dose gradually to minimize withdrawal (NCCN) 3.

Diphenhydramine can be used as an adjunct to standard antiemetic therapy but is not recommended as a single‑agent antiemetic (ASCO) 6, 7.
For patients with concurrent dyspepsia, adding an H₂‑blocker or proton‑pump inhibitor may improve symptom discrimination between heartburn and nausea (NCCN) 9, 8.